journal article·2006-03-15

In vitro hemocompatibility of albumin–heparin multilayer coatings on polyethersulfone prepared by the layer‐by‐layer technique

Claudia Sperling, Milan Houska, Eduard Brynda, Uwe Streller, Carsten Werner

Publisher page

Abstract

Abstract Polyethersulfone foils (PES)—a unique material for blood purification membranes—were coated with a multilayer assembly of heparin (unfractionated or high anticoagulant activity fraction heparin) and albumin (albumin–heparin coatings), or with a multilayer of albumin (albumin coating), using the layer‐by‐layer technique. The coatings combine advantages of albumin (reduction of nonspecific interactions) and heparin (specific interactions with blood coagulation proteins). The differences between the two heparins, while significant for their biological activity, had only a minor effect on the multilayer assembly with albumin monitored in situ by reflection infrared spectroscopy (FTIR MIRS). Uncoated as well as modified PES surfaces were evaluated using an in vitro assay with freshly drawn, slightly heparinized (1.5 IU heparin/mL) human whole blood. The blood was circulated with a roller pump over the sample surfaces in shear flow across rectangular slit channels ( app. 6 mL/min and 120 s−1) for 1.5 h at 37°C. All coatings effectively reduced platelet adhesion and activation according to the PF4 release. The activation of coagulation evaluated as TAT generation was significantly lowered for the coating composed of albumin and high activity heparin. A further beneficial effect of the heparin containing coatings was reduced complement activation as determined by different complement fragments. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res, 2006
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Polymer Surface Interaction Studies · Platelet Disorders and Treatments · Hemostasis and retained surgical items

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. 10.1016/j.biomaterials.2004.01.02310.1016/j.biomaterials.2004.01.023 ↗
2. 10.1016/S1010-7940(99)00210-910.1016/S1010-7940(99)00210-9 ↗
3. 10.1093/ndt/gfg41010.1093/ndt/gfg410 ↗
4. 10.1159/00006738910.1159/000067389 ↗
5. 10.1067/mtc.2001.11281810.1067/mtc.2001.112818 ↗
6. 10.1213/01.ANE.0000114551.64123.7910.1213/01.ANE.0000114551.64123.79 ↗
7. 10.1016/j.athoracsur.2003.09.02810.1016/j.athoracsur.2003.09.028 ↗
8. 10.1016/j.jss.2003.12.02610.1016/j.jss.2003.12.026 ↗
9. Reduction of subacute stent thrombosis (SAT) using heparin‐coated stents in a large‐scale, real world registry
10. 10.1159/00007758910.1159/000077589 ↗
11. Larm O · 1989 · 597
12. 10.1002/jbm.a.1010410.1002/jbm.a.10104 ↗
13. Czech Pat. 270919. (1990) (Appl. Dec. 30 1986)Academy of Sciences of the Czech Republic invs.:BryndaE HouskaM VacíkJ KálalJ NovikovaSP IlinaB SeleznevaMN DobrovaNB MPT A 61 L 33/00.
14. 10.1006/jcis.1996.051410.1006/jcis.1996.0514 ↗
15. 10.1006/jcis.1996.457610.1006/jcis.1996.4576 ↗
16. 10.1002/(SICI)1521-3927(19980401)19:4<173::AID-MARC173>3.0.CO;2-S10.1002/(SICI)1521-3927(19980401)19:4<173::AID-MARC173>3.0.CO;2-S ↗
17. 10.1002/(SICI)1097-4636(200008)51:2<249::AID-JBM14>3.0.CO;2-X10.1002/(SICI)1097-4636(200008)51:2<249::AID-JBM14>3.0.CO;2-X ↗
18. Brynda E · 2000 · 251
19. 10.1177/02676591980130030610.1177/026765919801300306 ↗
20. 10.1016/S0022-5223(99)70066-810.1016/S0022-5223(99)70066-8 ↗
21. 10.1016/0142-9612(89)90017-310.1016/0142-9612(89)90017-3 ↗
22. 10.1163/156856292X0019610.1163/156856292X00196 ↗
23. Deposition of a multilayered protein coating onto poly(ethylene terephtalate)
24. 10.1016/S0925-4005(98)00331-110.1016/S0925-4005(98)00331-1 ↗
25. 10.1016/S0956-5663(99)00013-510.1016/S0956-5663(99)00013-5 ↗
26. 10.1016/S0956-5663(02)00028-310.1016/S0956-5663(02)00028-3 ↗
27. Material surface modification with organized multilayer assemblies of biological macromolecules
28. 10.1002/(SICI)1521-3927(20000401)21:7<319::AID-MARC319>3.0.CO;2-710.1002/(SICI)1521-3927(20000401)21:7<319::AID-MARC319>3.0.CO;2-7 ↗
29. Lvov Y · 2000
30. 10.1002/352760057410.1002/3527600574 ↗
31. 10.1002/jbm.b.1001610.1002/jbm.b.10016 ↗
32. 10.1016/j.biomaterials.2003.10.09110.1016/j.biomaterials.2003.10.091 ↗
33. 10.1016/j.biomaterials.2003.12.01410.1016/j.biomaterials.2003.12.014 ↗
34. Cardioplumonary bypass without systemic heparinization. Performance of heparin‐coated oxygenators in comparison with classic membrane and bubble oxygenators10.1016/S0022-5223(19)34385-5 ↗
35. 10.1016/S0003-4975(00)01389-810.1016/S0003-4975(00)01389-8 ↗
36. 10.1016/S0003-4975(96)01054-510.1016/S0003-4975(96)01054-5 ↗
37. 10.1067/mtc.2002.12255110.1067/mtc.2002.122551 ↗
38. 10.1016/j.jcis.2003.12.05610.1016/j.jcis.2003.12.056 ↗
39. 10.1002/(SICI)1097-4636(19991205)47:3<279::AID-JBM1>3.0.CO;2-W10.1002/(SICI)1097-4636(19991205)47:3<279::AID-JBM1>3.0.CO;2-W ↗
40. 10.1182/blood.V99.1.15110.1182/blood.V99.1.151 ↗
41. 10.1016/S0142-9612(03)00470-810.1016/S0142-9612(03)00470-8 ↗
42. Heparin is not just an anticoagulant anymore: Six and one‐half decades of studies on the ability of heparin to regulate complement activity
43. 10.1016/S0003-4975(03)01519-410.1016/S0003-4975(03)01519-4 ↗
44. 10.1016/S0142-9612(00)00431-210.1016/S0142-9612(00)00431-2 ↗
45. 10.1097/00002480-200211000-0000510.1097/00002480-200211000-00005 ↗
46. Modulation of complement activation on hemodialysis membranes by immobilized heparin10.1681/ASN.V281328 ↗
47. 10.1016/0003-4975(95)01199-410.1016/0003-4975(95)01199-4 ↗
48. 10.1016/0161-5890(83)90139-610.1016/0161-5890(83)90139-6 ↗